Diabetes Technology Research Group

14/11/2025

This , we'd like to highlight this wonderful video of our study nurse and coordinator Jenna, who lives with Type 1 Diabetes. A number of our team members, including Jenna, have lived experience of managing diabetes in the workplace. Their dedication to advocacy and improving clinical outcomes for those living with diabetes are exceptional assets for our team, helping us to offer the best clinical care to our participants.

13/11/2025

Today is .
As part of the World Diabetes Day focus on diabetes and well-being, this year the International Diabetes Federation is calling for more inclusive and supportive workplaces where people with diabetes feel supported. By strengthening awareness and understanding, we can ensure workplaces where people living with diabetes feel safe, valued, and empowered to thrive.

13/11/2025

We are looking for people with type 1 diabetes and impaired hypoglycemia awareness to take part in a research study at St Vincent’s Hospital, Melbourne.
To enquire, please contact DTRG-t1research@unimelb.edu.au or 03 9231 2757.
Alternatively, follow this link to our website to express your interest:
https://www.diabetestechnologyresearchgroup.com.au/the-CLEAR-study/

30/10/2025

Important Notice for Potential Research Participants!
We appreciate your overwhelming interest in our research projects over the past few weeks!
Unfortunately, our "get in touch" form on our website experienced a malfunction, and submissions made before Tuesday 28th October were not received.
If you have recently made an enquiry, please resubmit your details so we can contact you!

https://www.diabetestechnologyresearchgroup.com.au/get-involved/

Thank you!

Get Involved with the D.T.R.G Diabetes clinical trials are an essential part of the development of new interventions

24/10/2025

Great news! D.T.R.G have been awarded a prestigious NIH Award, which will fund a new project investigating the use of SGLT inhibitors in people with type 1 diabetes! This project will be lead by Professor David O'Neal, Dr Dale Morrison, and Dr Audrey Kong (pictured left to right).

SGLT inhibitors have transformed the management of type 2 diabetes, saving countless lives by improving glycaemic control and significantly reducing cardiovascular and renal complications. However, their use in T1D has been limited due to the increased risk of diabetic ketoacidosis (DKA) when taking SGLT inhibitors, which can be life threatening.

This study will evaluate whether continuous glucose and ketone monitoring, combined with a tailored response algorithm, can help detect rising ketone levels early and prevent DKA, while allowing people with T1D to experience the many benefits SGLT inhibitors offer.

We are very excited to be bringing this study to Australians living with T1D, and we look forward to sharing the results of this important project in the future!

23/09/2025

Last week, D.T.R.G attended , represented by Dr David O'Neal, Dr Jean Lu, and Dr Jennifer Ngan. Pictured here is Dr Jennifer Ngan giving her presentation on the preliminary results of our PARTNER study, which involves the investigation of free-living ketone profiles collected by continuous ketone monitors in people with type 1 diabetes. To learn more about the findings of this investigation and for access to the publication, follow this link to our website - https://www.diabetestechnologyresearchgroup.com.au/dr-jennifer-ngan-presents-at-easd-2025/

23/09/2025

D.T.R.G are currently recruiting for the COYOTE study, investigating if using an automated insulin delivery system can improve glucose levels in people with type 2 diabetes. For any enquiries, please contact us on dtrg-t1research@unimelb.edu.au or visit our website at https://www.diabetestechnologyresearchgroup.com.au/the-coyote-study/

16/09/2025

This important trial is currently recruiting participants. To check your eligibility, follow the link to the Diabetes Victoria website:
https://www.diabetesvic.org.au/news-research/take-part-in-research-trials/research-trials-type-1-diabetes/mt-101-101-trial-for-type-1-diabetes/

The MT-101-101 study is a phase 1 clinical trial, testing the safety and dosing of a new treatment for autoimmune diseases including type 1 diabetes. They are looking for people:
🔵 Aged between 18 and 45 years
🔵 Diagnosed with type 1 diabetes
🔵 Residual C-peptide (a measure of insulin production
🔵 Currently using insulin (via injections or by pump)
🔵 Living in Victoria or NSW

If you match this criteria and are interested in being involved, click through and find out more >>> https://bit.ly/4poFcCe

07/09/2025

D.T.R.G are currently recruiting participants for a survey for adults with type 1 diabetes exploring nutrition, physical activity and dietary supplement use. Any adult with T1D in Australia is eligible. To complete the survey, scan the QR code in the flyer or follow the link below:
https://q.surveys.unimelb.edu.au/jfe/form/SV_57w0qJJH3Q5DstU

29/08/2025

D.T.R.G are currently recruiting for the OPAL 2 study, comparing the experience of using an Omnipod 5 pod pump to 'usual care' in people living with type 1 diabetes. For any enquiries, please contact us on dtrg-t1research@unimelb.edu.au or visit our website at https://www.diabetestechnologyresearchgroup.com.au/the-opal-2-study/

26/08/2025

That's a wrap on ! Our team had a wonderful time sharing the results of our last years worth of research output, and spending valuable time building connections with Australia's diabetes community. Thank you to the Australian Diabetes Educators Association and the Australian Diabetes Society for hosting this wonderful event!

20/08/2025

Yesterday was the first day of ! This year, more D.T.R.G team members than ever before are presenting the results of our last year's of research. Pictured here is Prof David O'Neal and Dr John Apostolopoulos, who both presented the ongoing findings of the REGENT-1 study investigating a new treatment for type 2 diabetes. To learn more about all the research we are sharing this week, head to our website through the link in our bio!